PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status

Stéphane Supiot, Helen Zhao, Klas Wiman, Richard P. Hill, Robert G. Bristow*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The novel agent PRIMA-1met can reactivate WTp53 function in MTp53-expressing cells. We investigated PRIMA-1met as a radiosensitizer of WTp53, p53Null or MTp53 prostate cancer cells. Radiosensitization was observed in PC3 (p53Null) cells, even under hypoxia. In certain circumstances, PRIMA-1met may therefore act independently of MTp53 status and WTp53 transactivation.

Original languageEnglish
Pages (from-to)407-411
Number of pages5
JournalRadiotherapy and Oncology
Volume86
Issue number3
DOIs
Publication statusPublished - Mar 2008

Keywords

  • Hypoxia
  • p53
  • PRIMA-1
  • Prostate cancer
  • Radiosensitizer

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'PRIMA-1met radiosensitizes prostate cancer cells independent of their MTp53-status'. Together they form a unique fingerprint.

Cite this